Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 265

1.

Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-α therapy during pregnancy: three-center study.

Bortlik M, Machkova N, Duricova D, Malickova K, Hrdlicka L, Lukas M, Kohout P, Shonova O, Lukas M.

Scand J Gastroenterol. 2013 Aug;48(8):951-8. doi: 10.3109/00365521.2013.812141. Epub 2013 Jul 8.

PMID:
23834232
2.

Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure.

Zelinkova Z, van der Ent C, Bruin KF, van Baalen O, Vermeulen HG, Smalbraak HJ, Ouwendijk RJ, Hoek AC, van der Werf SD, Kuipers EJ, van der Woude CJ; Dutch Delta IBD Group.

Clin Gastroenterol Hepatol. 2013 Mar;11(3):318-21. doi: 10.1016/j.cgh.2012.10.024. Epub 2012 Oct 25.

PMID:
23103819
3.

Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy.

Schnitzler F, Fidder H, Ferrante M, Ballet V, Noman M, Van Assche G, Spitz B, Hoffman I, Van Steen K, Vermeire S, Rutgeerts P.

Inflamm Bowel Dis. 2011 Sep;17(9):1846-54. doi: 10.1002/ibd.21583. Epub 2011 Jan 6.

PMID:
21830263
4.

Is safety infliximb during pregnancy in patients with inflammatory bowel disease?

Argüelles-Arias F, Castro-Laria L, Barreiro-de Acosta M, García-Sánchez MV, Guerrero-Jiménez P, Gómez-García MR, Cordero-Ruiz P, Iglesias-Flores E, Gómez-Camacho F, Domínguez-Muñoz EJ, Herrerías-Gutiérrez JM.

Rev Esp Enferm Dig. 2012 Feb;104(2):59-64.

6.

Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease.

Mahadevan U, Wolf DC, Dubinsky M, Cortot A, Lee SD, Siegel CA, Ullman T, Glover S, Valentine JF, Rubin DT, Miller J, Abreu MT.

Clin Gastroenterol Hepatol. 2013 Mar;11(3):286-92; quiz e24. doi: 10.1016/j.cgh.2012.11.011. Epub 2012 Nov 28.

7.

Anti-TNF antibody therapy for inflammatory bowel disease during pregnancy: a clinical review.

El Mourabet M, El-Hachem S, Harrison JR, Binion DG.

Curr Drug Targets. 2010 Feb;11(2):234-41. Review.

PMID:
19916950
8.

High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy.

Zelinkova Z, de Haar C, de Ridder L, Pierik MJ, Kuipers EJ, Peppelenbosch MP, van der Woude CJ.

Aliment Pharmacol Ther. 2011 May;33(9):1053-8. doi: 10.1111/j.1365-2036.2011.04617.x. Epub 2011 Mar 1.

9.

Safety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease.

Casanova MJ, Chaparro M, Domènech E, Barreiro-de Acosta M, Bermejo F, Iglesias E, Gomollón F, Rodrigo L, Calvet X, Esteve M, García-Planella E, García-López S, Taxonera C, Calvo M, López M, Ginard D, Gómez-García M, Garrido E, Pérez-Calle JL, Beltrán B, Piqueras M, Saro C, Botella B, Dueñas C, Ponferrada A, Mañosa M, García-Sánchez V, Maté J, Gisbert JP.

Am J Gastroenterol. 2013 Mar;108(3):433-40. doi: 10.1038/ajg.2012.430. Epub 2013 Jan 15.

PMID:
23318480
10.

Safety of TNF-α inhibitors during IBD pregnancy: a systematic review.

Nielsen OH, Loftus EV Jr, Jess T.

BMC Med. 2013 Jul 31;11:174. doi: 10.1186/1741-7015-11-174. Review.

11.

Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases.

Roblin X, Rinaudo M, Del Tedesco E, Phelip JM, Genin C, Peyrin-Biroulet L, Paul S.

Am J Gastroenterol. 2014 Aug;109(8):1250-6. doi: 10.1038/ajg.2014.146. Epub 2014 Jun 10.

PMID:
24913041
12.

Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.

Magro F, Portela F.

BioDrugs. 2010 Dec 14;24 Suppl 1:3-14. doi: 10.2165/11586290-000000000-00000. Review.

PMID:
21175228
13.

Serum Concentration of Anti-TNF Antibodies, Adverse Effects and Quality of Life in Patients with Inflammatory Bowel Disease in Remission on Maintenance Treatment.

Brandse JF, Vos LM, Jansen J, Schakel T, Ponsioen CI, van den Brink GR, D'Haens GR, Löwenberg M.

J Crohns Colitis. 2015 Nov;9(11):973-81. doi: 10.1093/ecco-jcc/jjv116. Epub 2015 Jun 26.

PMID:
26116557
14.

Pregnancy outcomes in women with inflammatory bowel disease following exposure to thiopurines and antitumor necrosis factor drugs: a systematic review with meta-analysis.

Mozaffari S, Abdolghaffari AH, Nikfar S, Abdollahi M.

Hum Exp Toxicol. 2015 May;34(5):445-59. doi: 10.1177/0960327114550882. Epub 2014 Nov 5.

PMID:
25378092
15.

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics.

Mahadevan U, Cucchiara S, Hyams JS, Steinwurz F, Nuti F, Travis SP, Sandborn WJ, Colombel JF.

Am J Gastroenterol. 2011 Feb;106(2):214-23; quiz 224. doi: 10.1038/ajg.2010.464. Epub 2010 Dec 14. Review.

PMID:
21157441
16.

Complications of pregnancy and child development after cessation of treatment with 6-mercaptopurine for inflammatory bowel disease.

Zlatanic J, Korelitz BI, Rajapakse R, Kim PS, Rubin SD, Baiocco PJ, Panagopoulos G.

J Clin Gastroenterol. 2003 Apr;36(4):303-9.

PMID:
12642735
17.

Mucosal healing in pediatric Crohn's disease after anti-TNF therapy: a long-term experience at a single center.

Nobile S, Gionchetti P, Rizzello F, Calabrese C, Campieri M.

Eur J Gastroenterol Hepatol. 2014 Apr;26(4):458-65. doi: 10.1097/MEG.0000000000000045.

PMID:
24445727
18.

Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study.

Coelho J, Beaugerie L, Colombel JF, Hébuterne X, Lerebours E, Lémann M, Baumer P, Cosnes J, Bourreille A, Gendre JP, Seksik P, Blain A, Metman EH, Nisard A, Cadiot G, Veyrac M, Coffin B, Dray X, Carrat F, Marteau P; CESAME Pregnancy Study Group (France).

Gut. 2011 Feb;60(2):198-203. doi: 10.1136/gut.2010.222893. Epub 2010 Nov 29.

PMID:
21115547
19.

Utility of serum TNF-α, infliximab trough level, and antibody titers in inflammatory bowel disease.

Pallagi-Kunstár É, Farkas K, Szepes Z, Nagy F, Szűcs M, Kui R, Gyulai R, Bálint A, Wittmann T, Molnár T.

World J Gastroenterol. 2014 May 7;20(17):5031-5. doi: 10.3748/wjg.v20.i17.5031.

20.

Comparative effectiveness of anti-TNF agents for Crohn's disease in a tertiary referral IBD practice.

Patil SA, Rustgi A, Langenberg P, Cross RK.

Dig Dis Sci. 2013 Jan;58(1):209-15. doi: 10.1007/s10620-012-2323-0. Epub 2012 Sep 27.

PMID:
23014844
Items per page

Supplemental Content

Write to the Help Desk